Polycystic Ovarian Syndrome Drugs Market is Expected to Exceed US$ 1,154.8 Mn by 2024
According
to the latest market report published by Persistence Market Research
titled ‘Polycystic Ovary Syndrome Drugs Market: Global Industry Analysis
and Forecast, 2016–2024’, the global polycystic ovary syndrome drugs
market is expected to register a CAGR of 4.6% during the forecast period
2016–2024 and is expected to expand 1.5x in terms of revenue by 2024.
The report analyzes the global PCOS drugs market performance and
provides information on key drivers and trends likely to impact the
market during the forecast period.
Growth
of the global polycystic ovary syndrome drugs market is mainly driven
by increasing prevalence of the disease and a growing awareness among
the patient population. Increasing purchasing power among people and
rising awareness of PCOS are factors expected to drive growth of the
global PCOS drugs market. The need for effective management of diseases
associated with PCOS such as hirsutism, obesity, and infertility is
likely to boost the demand for PCOS drugs. Also, a growing popularity of
combination drugs and their rising adoption among the patient
population is expected to boost revenue growth of the PCOS drugs market
in the coming years. A rising expenditure on research and development
activities and introduction of novel drugs is further expected to boost
growth of the global polycystic ovary syndrome drugs market over the
forecast period. However, lack of FDA approved drugs, a low level of
awareness of PCOS in underdeveloped countries, and increasing side
effects associated with generics might hamper market growth during the
forecast period.
Report overview @ https://www.persistencemarketresearch.com/market-research/polycystic-ovarian-syndrome-drugs-market.asp
The
global market for PCOS drugs presents several growth opportunities for
market players. There is a good growth potential in emerging markets and
pharmaceutical drugs manufacturers are focusing on emerging economies
in the Asia Pacific and Africa such as Kenya, Nigeria, etc. to target a
large patient population. Also, effective reimbursement policies and
reduction in the costs of drugs used for the treatment of PCOS is likely
to increase the adoption of PCOS drugs across the globe. Leading market
players are also investing significantly in developing new branded
drugs to treat PCOS, owing to an anticipated high rise in the global
patient population. The demand for branded PCOS drugs is likely to
increase significantly during the forecast period.
The
global PCOS drugs market is segmented based on Drug Class into Oral
Contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine
Decarboxylase Inhibitors, Aromatase Inhibitors, and Diuretics. The
contraceptive drug class segment is projected to register a CAGR of 5.4%
over the forecast period. Oral contraceptives are generally the
preferred first line therapy for the treatment of PCOS as they are
easily available as OTC drugs. The insulin sensitizing agent segment is
expected to register a CAGR of 4.8% over the forecast period. About 70%
of PCOS patients are overweight and are in the category of possible
candidates for type 2 diabetes. As a result, insulin sensitizing agents
are the widely prescribed drugs for the treatment of PCOS today. In
terms of value, the oral contraceptives and insulin sensitizing agents
drug class segments are collectively expected to remain the dominant and
most attractive segments over the forecast period.
Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/3682
The
global PCOS drugs market is segmented based on Distribution Channel
into Hospital Pharmacies, Drug Stores/OTC, E-Commerce, and Fertility
Clinics. The hospital pharmacies segment is likely to lead the global
PCOS drugs market in terms of revenue growth and is estimated to be
valued at US$ 575.4 Mn by the end of 2024. In terms of value, the drugs
stores/OTC segment is estimated to account for 27.0% share of the
overall market by the end of 2016.
On
the basis of region, the market has been segmented into North America,
Latin America, Europe, Asia Pacific, and the MEA. The North America
market is expected to emerge as the dominant market for polycystic ovary
syndrome drugs owing to a high diagnosis rate and increasing adoption
of prescription drugs. North America is estimated to dominate the PCOS
drugs market with maximum value share of the overall market by the end
of 2016. The presence of well-established pharmaceutical companies in
North America as well as a relatively high instance of patients being
diagnosed in hospitals for PCOS is a major driver for market growth. The
market in the Asia Pacific region is expected to register the highest
CAGR of 5.5% over the forecast period. Significant increase in
healthcare services spending along with rapid economic growth and
increasing awareness about health issues are some of the key factors
likely to push the sales of PCOS drugs in the APAC market.
Get Full Report now @ https://www.persistencemarketresearch.com/checkout/3682
The
report also includes detailed company profiles with company-specific
long-term and short-term strategies, key offerings, and recent
developments in the polycystic ovary syndrome therapeutics market. Some
of the leading companies profiled in the report are Sanofi, Novartis,
Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD,
Merck KGaA, and AstraZeneca Plc. These companies are primarily focused
on enhancing their product portfolio through research and development
activities and the introduction of innovative and cost-effective
treatment procedures in order to gain higher market share and to
strengthen their respective position in the global market.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
Comments
Post a Comment